Development and evaluation of copper-67 and samarium-153 labeled conjugates for tumor radioimmunotherapy

AbstractCopper-67 and samarium-153 are two of the most attractive radionuclides for radioimmunotherapy. Two to three-day halflives, intermediate-energy beta emissions, image-able photons, and suitable chemical characteristics make these radionuclides ideal for this application. Work on the production of high specific activity 67Cu and l53Sm, as well as the development of stable chelates for conjugating these radiometals to tumor-associated monoclonal antibodies is presented. Based on preliminary in vitro and in vivo studies (in nude mice xenografted with human colon carcinoma), both 67Cu and l53Sm appear very promising for tumor radioimmunotherapy and warrant continued investigation.

[1]  S. Larson,et al.  Current status of radioimmunotherapy. , 1994, Nuclear medicine and biology.

[2]  C. Chapman,et al.  Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  R. Howell,et al.  Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  S. Srivastava,et al.  Selection of radionuclides for radioimmunotherapy. , 1993, Medical physics.

[5]  Gansow Oa,et al.  An improved method for labeling monoclonal antibodies with samarium-153: use of the bifunctional chelate 2-(p-isothiocyanatobenzyl)-6- methyldiethylenetriaminepentaacetic acid. , 1992 .

[6]  T. Kaden,et al.  Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid. , 1991, Bioconjugate chemistry.

[7]  A. Dasgupta,et al.  A new separation procedure for 67Cu from proton irradiated Zn , 1991 .

[8]  S. Srivastava,et al.  Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[9]  W A Volkert,et al.  Therapeutic radionuclides: production and decay property considerations. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  S. Denardo,et al.  Macrocyclic chelates of radiometals for diagnosis and therapy. , 1990, The British journal of cancer. Supplement.

[11]  G. Meinken,et al.  Development of a new radiolabel (203Pb) and new chelating agents for labeling monoclonal antibodies for imaging. , 1990, Acta radiologica. Supplementum.

[12]  J. Turner,et al.  Labeling of monoclonal antibodies with samarium-153 for combined radioimmunoscintigraphy and radioimmunotherapy. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  A Vacca,et al.  Radioimmunotherapy of human colon carcinoma by 131I‐labelled monoclonal anti‐cea antibodies in a nude mouse model , 1988, International Journal of Cancer.

[14]  G. Denardo,et al.  Quantitative Pharmacokinetics of Radiolabeled Monoclonal Antibodies for Imaging and Therapy in Patients , 1988 .

[15]  S. Larson,et al.  The National Institutes of Health Experience with Radiolabeled Monoclonal Antibodies: Lymphoma, Melanoma, and Colon Cancer , 1988 .

[16]  S. Srivastava,et al.  Radiolabeled Monoclonal Antibodies for Imaging and Therapy , 1988, NATO ASI Series.

[17]  S. Adelstein,et al.  Radiobiologic implications of the microscopic distribution of energy from radionuclides. , 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[18]  G. Meinken,et al.  Correlating Labeling Chemistry and in-vitro Test Results with the Biological Behavior of Radiolabeled Proteins * , 1986, The International journal of biological markers.

[19]  S. Srivastava,et al.  Production of no-carrier added 67Cu. , 1986, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[20]  C. Meares,et al.  Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. , 1984, Analytical biochemistry.

[21]  R. G. Buckley,et al.  An efficient method for labelling antibodies with 111In , 1984, FEBS letters.

[22]  M. Welch,et al.  Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. , 1982, Radiation research.

[23]  L. Feinendegen.  Biological damage from the Auger effect, possible benefits , 1975, Radiation and environmental biophysics.

[24]  R. Silberberg,et al.  Partial Cross-Sections in High-Energy Nuclear Reactions, and Astrophysical Applications. I. Targets With z <= 28. , 1973 .